Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for hematological malignancies. Graft-versus-host disease (GVHD) is an important cause of graft failure and death. At present, the classic prevention program of GVHD is cyclosporine and calcineurin inhibitor (CNI; i.e. tacrolimus) plus methotrexate (CTX) or mycophenolate mofetil (MMF). However, the incidence of aGVHD is about 30-50%. Furthermore, the classic preventive regimen can also inhibit the graft-versus-leukemia effective (GVL) effect while reducing aGVHD, thereby increasing the recurrence rate, slowing the immune reconstitution, increasing the opportunistic infection. Ruxolitinib is a selective JAK1/2 small molecule kinase inhibitor, which has been reported to have a significant effect on the treatment of GVHD, while retaining the GVL effect with mild side effects. Sirolimus is a macrolide antibiotic with antifungal, immunosuppressive and antitumor effects. Based on the above studies, it can be speculated that the combination of ruxolitinib and sirolimus may have the function of immune inhibition, anti-tumor, while retaining the GVL effect, reducing the recurrence rate and reducing the risk of infection. Here we report our experience of using the combination of ruxolitinib and sirolimus to prevent the occurrence of aGVHD post to HLA matched hematopoietic stem cell transplantation and analyzed the incidence and prognosis of aGVHD.1. Patients and Methods1.1 Patients: There were five pati...
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
CONCLUSIONS: Tacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs. PMID: 33029975 [PubMed]
CONCLUSIONS: The SMs in PWIBDs and a craniotomy performed immediately before starting the process of determining brain death seem to be related to lengthening the TT-BD. PMID: 33029974 [PubMed]
CONCLUSION: DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC. Relapse to pre- and post-LT DAA therapy is associated with post-transplantation HCC recurrence. PMID: 33033569 [PubMed]
Authors: Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS Abstract Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. If diagnosed early, curative treatment options such as surgical resection, loco-regional therapies, and liver transplantation are available to patients, increasing their chances of survival and improving their quality of life. Unfortunately, most patients are diagnosed with late stage HCC where only palliative treatment is available. Therefore, biomarkers which could detect HCC early with a high degree of sensitivity and specificity, may play...
Authors: Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M Abstract Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chr...
This article reviews CTE disease based on its clinical and histological presentation, etiology and pathogenesis, and management and outcome. PMID: 33029133 [PubMed]
Publication date: Available online 10 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Zena Chahine, John Lister, Rodney E. Wegner, Santhosh Sadashiv
Authors: Takahashi M, Horio Y, Takihara T, Enokida K, Miyaoka M, Hirabayashi K, Ohshinden K, Hattori S, Takahashi F, Takahashi G, Tanaka J, Takiguchi H, Niimi K, Ito Y, Hayama N, Oguma T, Asano K Abstract A 72-year-old man was treated with prednisolone and cyclosporine A for idiopathic pulmonary fibrosis. A nodule with a diameter of 19 mm was found in the right lung and diagnosed as lung squamous cell carcinoma. Anti-cancer treatments were not performed because of the presence of advanced interstitial pneumonia and chronic respiratory failure. Cyclosporine A was tapered to avoid suppression of anti-tumor immunity, ...
Authors: Li H, Zhang J, Chen Y PMID: 33034436 [PubMed - as supplied by publisher]
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chronic Leukemia | Clinical Trials | Cystitis | Cytomegalovirus | Fungal Infections | Hematology | Leukemia | Liver | Liver Transplant | Methotrexate | Prograf | Restasis | Stem Cell Therapy | Stem Cells | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology